ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1666

Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study

Laura Cannon1, Anne Skelley-Caliendo2, Aimee Hersh3 and Andrea Knight4, 1Duke University, Durham, NC, 2Northwestern University, Chicago, IL, 3University of Utah and Primary Children's Hospital, Salt Lake City, 4Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: Pediatric rheumatology, Qualitative Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: An estimated 15 to 20% of patients with systemic lupus erythematosus (SLE) have childhood-onset SLE (cSLE). Given the early onset of cSLE, patients often experience significant burden due to cSLE  disease, comorbidities and immunosuppressive treatment. There is a pressing need for high quality, comprehensive research efforts to define the natural history, best treatments, access to care and disparities in care for cSLE patients. Building on a previously published survey study of clinicians caring for cSLE patients to describe research priorities in cSLE, the primary objective of this study was to conduct expert interviews to define a cSLE research agenda.

Methods: Individuals with identified expertise in cSLE were recruited worldwide using a purposive sampling technique including providers from several disciplines: pediatric rheumatology, pediatric nephrology, dermatology, psychiatry, medicine/pediatrics, and adolescent medicine. Experts participated in open-ended, semi-structured qualitative interviews. Interviews were designed to elicit expert perspectives on research priorities, optimal research approaches, and factors that facilitate and hinder advancing cSLE research. Interviews were digitally recorded, transcribed, and de-identified for qualitative analysis. 30 interviews were conducted between January and May 2020. Analysis for underlying themes of cSLE expert perspectives was performed using a constant comparative approach in which summaries and themes of each expert’s interview transcript informed the presence or absence of themes in subsequent cases (iteration). Two researchers conducted the analysis. To establish a consistent identification of themes, the first third of transcripts were analyzed by both researchers. The remaining transcripts were summarized by one researcher followed by a review from the second researcher to look for any missed additional elements.

Results: Several notable themes emerged from analysis of the interview data, supported by illustrative quotes (Table). A salient priority identified among interviewees was the importance of better (and more targeted) treatment for cSLE. Two major barriers to the development of new therapies were lack of pediatric clinical drug trials and need for biomarker research. Interviewees also identified individual investigator barriers to performing cSLE research, including obtaining funding to conduct projects, and having adequate time to conduct research. Last, collaboration was identified as a necessity within the cSLE research community, recognizing The Childhood Arthritis and Rheumatology Research Alliance (CARRA) as a powerful tool for multi-center collaboration in cSLE research.

Conclusion: cSLE expert interviewees identified the need for improved targeted therapies through pediatric clinical drug trials and biomarker research as well as collaboration between researchers and centers as research priorities. Funding and protected time for research are major individual barriers to involvement in cSLE research.

Table: Illustrative quotes from cSLE providers discussing research priorities and barriers to advancement of research for cSLE.


Disclosure: L. Cannon, None; A. Skelley-Caliendo, None; A. Hersh, None; A. Knight, None.

To cite this abstract in AMA style:

Cannon L, Skelley-Caliendo A, Hersh A, Knight A. Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/elucidating-research-priorities-in-childhood-onset-systemic-lupus-erythematosus-a-qualitative-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elucidating-research-priorities-in-childhood-onset-systemic-lupus-erythematosus-a-qualitative-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology